Background: Alcohol Withdrawal Syndrome (AWS) is a common, treatable, and preventable condition characterized by nausea, vomiting, hallucinations, agitation, headaches, and disorientation to place and time. Untreated, it can lead to chronic symptoms like delirium tremens. Lack of understanding of AWS complications, lack of awareness of alcohol abstinence, and HrQOL are the most threats to disease progression. In AWS patients, Pharmacist-led education on alcohol abstinence and medication adherence are critical measures of HrQOL improvement. Methods: The prospective observational study was conducted in the General medicine department. A total of 53 patients were recruited in the study. Before and following a three-month intervention, baseline demographics, revised Clinical Institute of Withdrawal Assessment scores, and health-related quality of life scores were documented to evaluate the quality of life. The obtained results were recorded and statistically evaluated using SPSS software version 26 for Windows. Results and Discussion: Out of 53 study participants. The majority of the patients were males 98.11% and 1.8% were females. Most of them were in the age group of 39-48. All the patients were treated with benzodiazepines, anticonvulsants, and other nutritional supplements were given. There is a positive correlation between the increasing age and years of alcohol consumption (p=0.97, significance = 0.492). The health progression of participants after treatment intervention and cognitive behavioral therapy of three months led to reduced CIWA and improved HrQOL scores (p < 0.05). Conclusion: Our study determined that continuous education and combined pharmacotherapies have reduced alcohol withdrawal symptoms and improved patient quality of life after the intervention assessment. The implementation of both pharmacological and cognitive behavioral therapies can improve the patient’s condition and enhance their quality of life.